ATE509918T1 - Substituierte 2-phenylbenzimidazole und ihre verwendung als pharmazeutika - Google Patents

Substituierte 2-phenylbenzimidazole und ihre verwendung als pharmazeutika

Info

Publication number
ATE509918T1
ATE509918T1 AT07802352T AT07802352T ATE509918T1 AT E509918 T1 ATE509918 T1 AT E509918T1 AT 07802352 T AT07802352 T AT 07802352T AT 07802352 T AT07802352 T AT 07802352T AT E509918 T1 ATE509918 T1 AT E509918T1
Authority
AT
Austria
Prior art keywords
compounds
formula
synthase
expression
endothelial
Prior art date
Application number
AT07802352T
Other languages
English (en)
Inventor
Gerhard Zoller
Hartmut Strobel
David Will
Paulus Wohlfart
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE509918T1 publication Critical patent/ATE509918T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07802352T 2006-09-30 2007-09-18 Substituierte 2-phenylbenzimidazole und ihre verwendung als pharmazeutika ATE509918T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06020654A EP1905764A1 (de) 2006-09-30 2006-09-30 Substituierte 2-Phenylbenzimidazole und ihre Verwendung als Pharmazeutika
PCT/EP2007/008104 WO2008037381A1 (en) 2006-09-30 2007-09-18 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
ATE509918T1 true ATE509918T1 (de) 2011-06-15

Family

ID=37680690

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07802352T ATE509918T1 (de) 2006-09-30 2007-09-18 Substituierte 2-phenylbenzimidazole und ihre verwendung als pharmazeutika

Country Status (5)

Country Link
US (1) US8168665B2 (de)
EP (2) EP1905764A1 (de)
JP (1) JP5298019B2 (de)
AT (1) ATE509918T1 (de)
WO (1) WO2008037381A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5782234B2 (ja) * 2010-06-16 2015-09-24 チャイナ メディカル ユニヴァーシティーＣｈｉｎａ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ ベンゾイミダゾール化合物およびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO2000003746A2 (en) 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
CN1363880A (zh) 2001-01-11 2002-08-14 张逶 一种信息镶嵌技术
AR035431A1 (es) 2001-02-13 2004-05-26 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
EP1388341A1 (de) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Substituierte Acylamino heteroaromatische Verbindungen und ihre Verwendung als Arztneimittel
EP1388342A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylierte, Heteroaryl-kondensierte Cycloalkenylamine und deren Verwendung als Arzneimittel
EP1388535A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylierte Arylcycloalkylamine und ihre Anwendung als Arzneimittelwirkstoff
EP1471066A1 (de) 2003-04-24 2004-10-27 Aventis Pharma Deutschland GmbH Triaza- und Tetraaza-anthrazendionderivate, ihre Herstellung und Verwendung als Pharmazeutika
CA2587489C (en) * 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto

Also Published As

Publication number Publication date
WO2008037381A1 (en) 2008-04-03
US20090239915A1 (en) 2009-09-24
JP2010505756A (ja) 2010-02-25
EP1905764A1 (de) 2008-04-02
EP2079709A1 (de) 2009-07-22
JP5298019B2 (ja) 2013-09-25
EP2079709B1 (de) 2011-05-18
US8168665B2 (en) 2012-05-01

Similar Documents

Publication Publication Date Title
ATE554765T1 (de) Imidazoä1,2-aüpyridine und ihre verwendung als arzneimittel
WO2008074413A3 (en) Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial no synthase
TW200800941A (en) Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
DE60319711D1 (de) Acylamino-substituierte heteroaromatische verbindungen und ihre verwendung als arzneimittel
MY141885A (en) Acylated arylcycloalkylamines and their use as pharmaceuticals
NO20074647L (no) 3,4 dihydro-1H-isoquinolin-2-karboksylsyre-5-ammopyridin-2-yl estere
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
NO20063928L (no) Substituerte kinolinforbindelser
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
WO2005077950A3 (en) Medicaments with hm74a receptor activity
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
BRPI0410466A (pt) derivados de indol como inibidores de fator xa
ATE494926T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
NO20080523L (no) Heteroarylsubstituerte amider omfattende en mettet bindingsgruppe og deres anvendelse som farmasoytiske midler
NO20064659L (no) Nye kvarterniserte quinuklidin-estere
MXPA05011267A (es) Derivados de la triaza-y tetraaza-antracenodiona, su preparacion y su uso como productos farmaceuticos.
ATE401877T1 (de) Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
DE602007012289D1 (de) Imidazoä2,1-büthiazole und ihre verwendung als pharmazeutika
DE602005027677D1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties